Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 8/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464150 | 1.00 | THRA (0.33) | THRATHRBSLC13A5CHRM2CHRM1 | |
| SCHEMBL3437747 | 1.00 | THRA (0.33) | THRATHRBSLC13A5CHRM2CHRM1 | |
| SCHEMBL1465423 | 0.90 | SYK (0.32) | THRATHRBCHRM2CHRM1CYP2D6 | |
| SCHEMBL14596706 | 0.89 | PTGDR (0.35) | SLC13A5SYKPTGDR2 | |
| SCHEMBL12748354 | 0.88 | KMT2A (0.34) | SYK | |
| SCHEMBL3437561 | 0.86 | PTGDR (0.33) | SYKPTGDR2 | |
| SCHEMBL12748374 | 0.85 | SYK (0.32) | SYK | |
| SCHEMBL4697247 | 0.84 | KMT2A (0.36) | SYK | |
| SCHEMBL12827205 | 0.84 | KMT2A (0.36) | SYK | |
| SCHEMBL11094402 | 0.76 | SSTR4 (0.37) | CHRM2CHRM1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070187-A1 | Methods for the Preparation of HCV Polymerase Inhibitors | PFIZER INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070187-A1 | Methods for the Preparation of HCV Polymerase Inhibitors | PFIZER INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070187-A1 | Methods for the Preparation of HCV Polymerase Inhibitors | PFIZER INC. | 2011-03-24 | — | — | US | disclosed |
| US-7807838-B2 | Methods for the preparation of HCV polymerase inhibitors | PFIZER INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807838-B2 | Methods for the preparation of HCV polymerase inhibitors | PFIZER INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807838-B2 | Methods for the preparation of HCV polymerase inhibitors | PFIZER INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090023921-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC | 2009-01-22 | — | — | US | disclosed |
| US-20090023921-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC | 2009-01-22 | — | — | US | disclosed |
| US-20090023921-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC | 2009-01-22 | — | — | US | disclosed |
| EP-1928878-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007023381-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023381-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023921-A1 | METHODS FOR THE PREPARATION OF HCV POLYMERASE INHIBITORS | POLRMT, POLI, POLM | THRA 4557/4885THRB 4148/4885SLC13A5 4150/4885 |
| US-20110070187-A1 | Methods for the Preparation of HCV Polymerase Inhibitors | POLRMT, POLI, POLM | THRA 4557/4885THRB 4148/4885SLC13A5 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.